Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ORMP Oramed Pharmaceuticals Inc.
$3.90 5.12% +0.19
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ORMP stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Oramed Pharmaceuticals Inc. (ORMP)

Loading

Key Stats

Market cap. 169.6M
Enterprise value 109.1M
Trailing PE 0.89830506
Forward PE -46.375
PEG Ratio 0.0018193520202532
Enterprise to EBITDA -6.785
Enterprise to revenue 54.547424
Price to book MRQ 0.4730936
Price to sales TTM 84.7975865

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 2.0M
EBITDA -16080000
Diluted EPS TTM 4.13
Total Cash (MRQ) 53.8M
Current ratio (MRQ) 6.074
Operating Cash Flow (TTM) -3155000

ORMP trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ORMP News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.